Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 1;120(15):2371-8.
doi: 10.1002/cncr.28699. Epub 2014 May 2.

Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy

Christine Miaskowski  1 , Bruce A Cooper, Michelle Melisko, Lee-May Chen, Judy Mastick, Claudia West, Steven M Paul, Laura B Dunn, Brian L Schmidt, Marilyn Hammer, Frances Cartwright, Fay Wright, Dale J Langford, Kathryn Lee, Bradley E Aouizerat
Affiliations

Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy

Christine Miaskowski et al. Cancer. .

Abstract

Background: A large amount of interindividual variability exists in the occurrence of symptoms in patients receiving chemotherapy (CTX). The purposes of the current study, which was performed in a sample of 582 oncology outpatients who were receiving CTX, were to identify subgroups of patients based on their distinct experiences with 25 commonly occurring symptoms and to identify demographic and clinical characteristics associated with subgroup membership. In addition, differences in quality of life outcomes were evaluated.

Methods: Oncology outpatients with breast, gastrointestinal, gynecological, or lung cancer completed the Memorial Symptom Assessment Scale before their next cycle of CTX. Latent class analysis was used to identify subgroups of patients with distinct symptom experiences.

Results: Three distinct subgroups of patients were identified (ie, 36.1% in Low class; 50.0% in Moderate class, and 13.9% in All High class). Patients in the All High class were significantly younger and more likely to be female and nonwhite, and had lower levels of social support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity.

Conclusions: Findings from the current study support the clinical observation that some oncology patients experience a differentially higher symptom burden during CTX. These high-risk patients experience significant decrements in quality of life.

Keywords: chemotherapy; latent class analysis; precision medicine; quality of life; symptom clusters; symptom profiles.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Probability of symptom occurrence for the total sample (i.e., sample proportion) and each of the latent classes for the 25 symptoms on the Memorial Symptom Assessment Scale that occurred in ≥40% of the total sample (n=582).
Figure 2
Figure 2
Figure 2A – Differences among the latent classes in the subscale and summary scores for the Medical Outcomes Study-Short Form 12 (SF-12). All values are plotted as means ± standard deviations. Significant differences: For PF: Low>Moderate (p<.0001>All High (p=.002). For RP, BP, SF, RE, MH, and MCS: Low>Moderate>All High (both p<.0001 for gh: low>Moderate and All High (p<.0001 for vt: low>Moderate (p<.0001>All High (p=.037). For PCS: Low>Moderate (p<.0001> All High (p=.006). Abbreviations: PF=physical functioning, RP=role physical, BP=bodily pain, GH=general health, VT=vitality, SF=social functioning, RE=role emotional, MH=mental health, PCS=physical component summary, MCS=mental component summary. Figure 2B - Differences among the latent classes in the subscale and total quality of life (QOL) scores for the Quality of Life Scale-Patient Version (QOL-PV). All values are plotted as means ± standard deviations. Significant differences: Physical, Psychological, and Social Functioning subscales and total QOL scores: Low>Moderate>All High (both p<.0001>
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Esther Kim JE, Dodd MJ, Aouizerat BE, Jahan T, Miaskowski C. A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Symptom Manage. 2009;37:715–736. - PMC - PubMed
    1. Pud D, Ben Ami S, Cooper BA, et al. The symptom experience of oncology outpatients has a different impact on quality-of-life outcomes. J Pain Symptom Manage. 2008;35:162–170. - PubMed
    1. Dodd MJ, Cho MH, Cooper BA, et al. Identification of latent classes in patients who are receiving biotherapy based on symptom experience and its effect on functional status and quality of life. Oncol Nurs Forum. 2011;38:33–42. - PubMed
    1. Dodd MJ, Cho MH, Cooper BA, Miaskowski C. The effect of symptom clusters on functional status and quality of life in women with breast cancer. Eur J Oncol Nurs. 2010;14:101–110. - PMC - PubMed
    1. Illi J, Miaskowski C, Cooper B, et al. Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine. 2012;58:437–447. - PMC - PubMed

Publication types